Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

NCT03320642 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03320642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03320642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Terminated
Start date
February 27, 2018
Completion date
February 17, 2022
Enrollment
84 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies